Pherecydes Pharma Logo

Pherecydes Pharma

ALPHE | PA

Overview

Corporate Details

ISIN(s):
FR0011651694
LEI:
894500LYT3UUN58X3I68
Country:
France
Address:
22 BD BENONI GOULLIN, NANTES BIOTECH, 44200 NANTES
Sector:
Health Care
Industry:
Biotechnology

Description

Pherecydes Pharma develops antibacterial treatments based on the use of bacteriophage viruses, or phages, to fight bacterial infections in humans, particularly those resistant to antibiotics. Phages are natural predators of bacteria and have no demonstrated effect on eukaryotic cells, including human cells. Antimicrobial resistant bacteria or AMR are responsible for over 700,000 death a year in 2014 according to the WHO. This number might reach over 10,000,000 by 2050 if nothing is done, and no new class of antibiotics has been discovered in the last 30 years. Phages represent one of the most promising approach to fight these AMR infections. Pherecydes Pharma has introduced the concept of precision phagotherapy, which consists in treating each patient according to the activity of the phages on the bacterial strain responsible for the infection. Treatments are therefore individualized and adapted to each case.

Social Media

Market Data

Market Data Not Available

Financials & KPIs

No data available

No Financial Data Available

Standardized financial statements for the selected period are not yet available.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Date Filing Language Size Actions
2023-06-23 20:45
Declaration of Voting Results & Voting Rights Announcements
Informations privilégiées / Autres communiqués
French 214.3 KB
2023-06-23 20:45
Regulatory News Service
Inside Information / Other news releases
English 213.8 KB
2023-06-14 20:00
Inside Information Statement
Inside Information / Other news releases
English 197.1 KB
2023-06-14 20:00
Inside Information Statement
Informations privilégiées / Autres communiqués
French 200.6 KB
2023-06-08 07:30
Inside Information Statement
Informations privilégiées / Autres communiqués
French 297.3 KB
2023-06-08 07:30
Inside Information Statement
Inside Information / Other news releases
English 269.4 KB
2023-06-05 08:00
Legal Proceedings Report
Inside Information / Other news releases
English 198.4 KB
2023-06-05 08:00
Legal Proceedings Report
Informations privilégiées / Autres communiqués
French 192.1 KB
2023-06-02 20:00
General Meeting Notice
Modalités de mise à disposition des documents préparatoires à l'AG
French 152.4 KB
2023-05-23 23:43
Regulatory News Service
News releases during takeover bids / Takeover bids Other news releases
English 191.8 KB
2023-05-23 23:43
Regulatory News Service
Communiqués publiés en période d'offre publique d'acquisition / OPA Autres comm…
French 184.9 KB
2023-05-16 07:00
Inside Information Statement
Inside Information / Other news releases
English 224.2 KB
2023-05-16 07:00
Inside Information Statement
Informations privilégiées / Autres communiqués
French 216.3 KB
2023-05-11 18:00
Regulatory News Service
Acquisition ou cession des actions de l'émetteur / Information relative au cont…
French 200.6 KB
2023-04-27 18:00
Report Publication Announcement
Rapports financiers et d'audit annuels / Modalités de mise à disposition du rap…
French 195.2 KB

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Company Country Ticker View
Herantis Pharma Oyj Logo Herantis Pharma Oyj Finland HRTIS
Hiron-Trade Investments & Industrial Buildings Ltd. Israel HRON
Human Stem Cells Institute PJSC Logo Human Stem Cells Institute PJSC Russian Federation ISKJ
Human Xtensions Ltd. Logo Human Xtensions Ltd. Israel HUMX
Hybrigenics SA Logo Hybrigenics SA France ALHYG
Hyloris Pharmaceuticals SA Logo Hyloris Pharmaceuticals SA Belgium HYL
Ikonisys S.A. Logo Ikonisys S.A. France ALIKO
IMCB PJSC Logo IMCB PJSC Russian Federation GEMA
Inify Laboratories AB Logo Inify Laboratories AB Sweden INIFY
Innate Pharma Logo Innate Pharma France IPH